Feature
Cardiovascular Systems Inc. (CSI) has presented 30-day results from its ORBIT II study of coronary artery disease. ORBIT II is evaluating the safety and effectiveness of the company’s orbital atherectomy technology in treating patients with severely calcified coronary lesions. This is the first Investigational Device Exemption study to evaluate this problematic subset of patients. CSI completed ORBIT II enrollment of 443 patients at 49 U.S. medical centers in November 2012 and submitted its Premarket Approval application to the U.S. Food and Drug Administration (FDA) on March 15, 2013.
May 29, 2013
Feature | Jeffrey M. Schussler M.D., FACC, FSCAI, FSCCT, FACP
Transradial coronary artery angiography was a major focus at the Society for Cardiovascular Angiography Interventions (SCAI) 2013 Scientific Sessions May 8-11 in Orlando, Fla. The meeting kicked-off with a dedicated symposium covering topics such as access, radiation exposure and complications.
May 29, 2013
Technology
Philips Healthcare announced that CX50 xMatrix, the first portable ultrasound with Philips' Live 3-D transesophageal echo (TEE), now offers 2-D intracardiac echo (ICE) capability. The CX50 xMatrix with available Live 3-D TEE and ICE was first shown in Paris at the EuroPCR in May.
May 29, 2013Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024
News
The Lotus Valve, a second-generation transcatheter aortic valve implantation (TAVI) device, was successfully implanted in all of the first 60 patients in results from REPRISE II, which showed good device performance and low mortality at 30 days.
May 29, 2013
News
The U.S. District Court for the District of New Jersey approved an agreement under which Vascular Solutions Inc. will cease further manufacture, sales and distribution of its R-Band Radial Hemostasis Device, pending litigation of Terumo Medical's patent infringement claims.
May 28, 2013
News
Direct Flow Medical Inc. said it met its primary endpoint in the fully-enrolled, 100-patient DISCOVER CE mark trial by achieving 99 percent freedom from all-cause mortality at 30 days. Patients were treated with the Direct Flow Medical Transcatheter Aortic Valve System and demonstrated excellent results relative to overall patient hemodynamics, as well as the avoidance of post-procedural aortic regurgitation and adverse events. The DISCOVER Trial full 30-day outcomes were presented today by trial investigator Joachim Schofer, M.D., from the Medical Care Center, Hamburg, Germany.
May 28, 2013Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024
News
Abbott announced CE mark in Europe for the Xience Xpedition 48 Everolimus Eluting Coronary Stent System, the first-of-its-kind treatment for very long blockages in the vessels that supply blood to the heart due to coronary artery disease (CAD).
May 28, 2013
News
CardioKinetix Inc. announced results of a meta-analysis study of the catheter-based Parachute Ventricular Partitioning Device. Six-month clinical results from 91 U.S. and European patients with ischemic heart failure were presented.
May 28, 2013
Feature
InspireMD Inc. announced new six-month results from the MASTER trial demonstrating that the MGuard embolic protection stent (EPS) outperformed bare metal stents and drug-eluting stents in all-cause mortality in ST-segment elevation myocardial infarction (STEMI) patients.
May 24, 2013Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023
Technology
Welch Allyn has released its new FlexiPort EcoCuff blood pressure cuff and EarlySense Vitals surveillance system. Both products enable improvements in patient safety and clinical decision-making to help reduce risk for facilities.
May 24, 2013
News
Although not designed for cardiovascular surgery, a new robotic surgical system being developed will likely add to the growing interest of using magnetic resonance imaging (MRI) as a replacement for X-ray angiographic interventional procedural guidance.
May 24, 2013
News
Neovasc Inc. reported positive animal data from its Tiara program for the transcatheter treatment of mitral valve disease. Data presented is on long-term implantation of the Tiara mitral replacement valve in an animal model of mitral regurgitation (MR).
May 24, 2013Sponsored Content
Case Study | Hemodynamic Monitoring Systems
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 14, 2023
Technology
Syntermed Inc. has been awarded 510(k) clearance for Emory Cardiac Toolbox version 4.0. "One of the many things that makes Emory Toolbox 4.0 different is SmartReport, the first-ever, cloud-based nuclear cardiology reporting tool using decision support,” said Michael Lee, CEO, Syntermed Inc. The decision support system that powers SmartReport is called Syntermed IDS and will allow diagnosticians to perform faster, more accurate nuclear cardiology reports from single photon emission computed tomography (SPECT) and positron emission tomography (PET) heart scans.
May 23, 2013
Feature
Intermountain Healthcare, a Utah-based nonprofit system of 22 hospitals and 185 clinics, is compiling the cumulative radiation patients receive from about 220,000 higher-dose procedures and imaging exams each year, starting with exams performed in the last quarter of 2012. That information is now readily available to both physicians and patients.
May 23, 2013Feature
Unavoidable damage caused to the heart and lungs by radiotherapy treatment of tumors in the chest region can be limited by the administration of an ACE inhibitor, a drug commonly used in the treatment of cardiovascular disease, a group of Dutch researchers have found. [1]
May 21, 2013© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now